Fresenius Medical Care AG (NYSE:FMS) Short Interest Down 5.1% in December

Fresenius Medical Care AG (NYSE:FMS) was the target of a large decrease in short interest during the month of December. As of December 15th, there was short interest totalling 808,800 shares, a decrease of 5.1% from the November 30th total of 852,500 shares. Based on an average daily trading volume, of 272,600 shares, the days-to-cover ratio is presently 3.0 days.

Institutional Investors Weigh In On Fresenius Medical Care

Several hedge funds have recently modified their holdings of FMS. JPMorgan Chase & Co. raised its stake in shares of Fresenius Medical Care by 18.2% in the third quarter. JPMorgan Chase & Co. now owns 9,902 shares of the company’s stock valued at $211,000 after acquiring an additional 1,528 shares in the last quarter. Franklin Resources Inc. raised its holdings in Fresenius Medical Care by 3.3% in the third quarter. Franklin Resources Inc. now owns 74,640 shares of the company’s stock valued at $1,490,000 after acquiring an additional 2,386 shares in the last quarter. Wilmington Savings Fund Society FSB acquired a new position in Fresenius Medical Care during the 3rd quarter worth approximately $38,000. MML Investors Services LLC increased its position in shares of Fresenius Medical Care by 5.3% in the 3rd quarter. MML Investors Services LLC now owns 15,019 shares of the company’s stock valued at $320,000 after purchasing an additional 753 shares during the last quarter. Finally, XTX Topco Ltd grew its stake in shares of Fresenius Medical Care by 70.8% during the third quarter. XTX Topco Ltd now owns 39,769 shares of the company’s stock worth $847,000 after purchasing an additional 16,487 shares in the last quarter. 8.37% of the stock is owned by hedge funds and other institutional investors.

Fresenius Medical Care Stock Performance

FMS stock opened at $22.71 on Tuesday. The firm has a market cap of $13.33 billion, a price-to-earnings ratio of 18.77, a PEG ratio of 0.96 and a beta of 0.94. Fresenius Medical Care has a one year low of $17.93 and a one year high of $24.31. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.02 and a current ratio of 1.37. The firm has a 50-day simple moving average of $22.13 and a two-hundred day simple moving average of $20.60.

Wall Street Analyst Weigh In

FMS has been the subject of a number of research reports. Berenberg Bank assumed coverage on shares of Fresenius Medical Care in a research note on Wednesday, November 6th. They issued a “buy” rating and a $25.60 price objective for the company. Bank of America raised shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research report on Monday, December 2nd. Truist Financial increased their price objective on shares of Fresenius Medical Care from $22.00 to $23.00 and gave the company a “hold” rating in a research report on Monday, October 7th. Finally, StockNews.com assumed coverage on Fresenius Medical Care in a report on Thursday, November 28th. They set a “strong-buy” rating on the stock. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $24.30.

About Fresenius Medical Care

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.